Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sriram Krishnaswami

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Clinical Therapeutics|January 26, 2008
Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled studyRaymond Cheung, Sriram Krishnaswami, Ken Kowalski
Best Practice & Research. Clinical Rheumatology|August 25, 2010
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomesRichard J Riese, Sriram Krishnaswami, Joel Kremer
Journal of Clinical Pharmacology|December 15, 2010
A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participantsSriram Krishnaswami, Elizabeth Kudlacz, Rong Wang, et al.
American Journal of Therapeutics|September 9, 2005
Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release modelShashank Rohatagi, Sriram Krishnaswami, Marc Pfister, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 7, 2007
Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patientsMatthew M Hutmacher, Sriram Krishnaswami, Kenneth G Kowalski
CPT: Pharmacometrics & Systems Pharmacology|October 18, 2023
Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncologyPriya Jayachandran, Rajat Desikan, Sriram Krishnaswami, et al.
The New England Journal of Medicine|September 18, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisBethanie Wilkinson, Sriram Krishnaswami, Ronald F van Vollenhoven
Clinical Pharmacology in Drug Development|April 30, 2016
Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteersSriram Krishnaswami, Mary Boy, Vincent Chow, et al.
Journal of Clinical Pharmacology|September 13, 2019
Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis PatientsMisaki Suzuki, Satoshi Shoji, So Miyoshi, et al.
Statistics in Medicine|April 8, 2011
Estimating transformations for repeated measures modeling of continuous bounded outcome dataMatthew M Hutmacher, Jonathan L French, Sriram Krishnaswami, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Clinical Therapeutics|January 26, 2008
Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled studyRaymond Cheung, Sriram Krishnaswami, Ken Kowalski
Best Practice & Research. Clinical Rheumatology|August 25, 2010
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomesRichard J Riese, Sriram Krishnaswami, Joel Kremer
Journal of Clinical Pharmacology|December 15, 2010
A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participantsSriram Krishnaswami, Elizabeth Kudlacz, Rong Wang, et al.
American Journal of Therapeutics|September 9, 2005
Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release modelShashank Rohatagi, Sriram Krishnaswami, Marc Pfister, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 7, 2007
Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patientsMatthew M Hutmacher, Sriram Krishnaswami, Kenneth G Kowalski
CPT: Pharmacometrics & Systems Pharmacology|October 18, 2023
Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncologyPriya Jayachandran, Rajat Desikan, Sriram Krishnaswami, et al.
The New England Journal of Medicine|September 18, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisBethanie Wilkinson, Sriram Krishnaswami, Ronald F van Vollenhoven
Clinical Pharmacology in Drug Development|April 30, 2016
Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteersSriram Krishnaswami, Mary Boy, Vincent Chow, et al.
Journal of Clinical Pharmacology|September 13, 2019
Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis PatientsMisaki Suzuki, Satoshi Shoji, So Miyoshi, et al.
Statistics in Medicine|April 8, 2011
Estimating transformations for repeated measures modeling of continuous bounded outcome dataMatthew M Hutmacher, Jonathan L French, Sriram Krishnaswami, et al.
Pageof 6